AstraZeneca invests nearly $30 million to upgrade base in China
17/09/2026 04:38
AstraZeneca invests nearly $30 million to upgrade base in China BEIJING, Sept 17 (Reuters) - AstraZeneca AZN.L unveiled an investment of nearly 200 million yuan ($29.81 million) to upgrade its production and supply base in Wuxi, China, the company's Chinese unit said in a statement on Thursday.
The upgraded facility, which will be used for development and production of AstraZeneca's innovative cardiovascular drugs, is expected to be operational in the last quarter of 2029, the pharmaceutical firm said.
($1 = 6.7085 Chinese yuan renminbi)
(Reporting by Liz Lee and Qiaoyi Li; Editing by Thomas Derpinghaus)
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines